The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).
 
Daniel H. Ahn
Consulting or Advisory Role - Astellas Pharma; Cardinal Health; Celltrion (I); Eisai; Exelixis; Lexicon
 
Afsaneh Barzi
Consulting or Advisory Role - Bayer Technology System; bioTheranostics; Merrion
Research Funding - Bayer (Inst); Merck (Inst)
 
Maya Ridinger
Employment - Trovagene
Stock and Other Ownership Interests - Trovagene
Travel, Accommodations, Expenses - Trovagene
 
Errin Samuelsz
Employment - Trovagene
Stock and Other Ownership Interests - Trovagene
 
Mark G. Erlander
Employment - Trovagene
Stock and Other Ownership Interests - Trovagene
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Bayer (Inst); Celgene (Inst); Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - ARMO BioSciences; AstraZeneca; Exelixis; Merck (Inst); Sillajen
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono